Cresco Labs (OTCMKTS:CRLBF - Get Free Report) was downgraded by stock analysts at Cormark from a "moderate buy" rating to a "hold" rating in a research report issued to clients and investors on Monday,Zacks.com reports. Cormark also issued estimates for Cresco Labs' FY2024 earnings at ($0.21) EPS and FY2025 earnings at $0.03 EPS.
Several other equities analysts have also commented on the stock. Ventum Cap Mkts raised shares of Cresco Labs to a "strong-buy" rating in a report on Friday, August 9th. Roth Capital raised shares of Cresco Labs to a "strong-buy" rating in a report on Sunday. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Cresco Labs in a report on Monday, August 12th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $2.50.
Get Our Latest Analysis on Cresco Labs
Cresco Labs Price Performance
OTCMKTS:CRLBF traded up $0.18 during trading hours on Monday, hitting $1.44. The stock had a trading volume of 919,928 shares, compared to its average volume of 752,714. Cresco Labs has a one year low of $1.02 and a one year high of $2.65. The company has a 50 day simple moving average of $1.58 and a two-hundred day simple moving average of $1.70. The company has a debt-to-equity ratio of 1.76, a current ratio of 2.00 and a quick ratio of 1.30. The firm has a market capitalization of $702.92 million, a price-to-earnings ratio of -7.20 and a beta of 1.88.
Cresco Labs Company Profile
(
Get Free Report)
Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.
Featured Articles
Before you consider Cresco Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cresco Labs wasn't on the list.
While Cresco Labs currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.